| Active substance | Pegcetacoplan |
| Holder | Swedish Orphan Biovitrum AB (publ) |
| Status | Running |
| Indication | Treatment of primary immune complex and C3-mediated glomerulopathy |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent parent(s) | |
| Informed consent adult | |
| Informed consent adolescent (12 - 17 years) | |
| Last update | 21/03/2025 |